SCHEMBL19274665

SCHEMBL19274665

CCCCOC(=O)c1cc(Sc2cnc(CNC(=O)OC(C)(C)C)s2)cc(-c2ccc(C)nc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.38
LOXL2 Q9Y4K0 3/20 0.34
MAPT P10636 4/20 0.33
KMT2A Q03164 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
ESR1 P03372 3/20 0.32
TGFBR1 P36897 1/20 0.32
HPGD P15428 2/20 0.31
RAB9A P51151 2/20 0.31
MEN1 O00255 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
DYRK1A Q13627 1/20 0.31
LOXL3 P58215 1/20 0.31
TP53 P04637 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30
SLC2A1 P11166 1/20 0.30
CSNK2A2 P19784 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29971072 0.91 PDPK1 (0.41) PDPK1LOXL2L3MBTL1DYRK1ALOXL3
SCHEMBL28644252 0.91 PDPK1 (0.41) PDPK1LOXL2L3MBTL1DYRK1ALOXL3
SCHEMBL19274640 0.90 LOXL2 (0.40) PDPK1LOXL2MAPTL3MBTL1CNR2
SCHEMBL30699957 0.90 LOXL2 (0.40) PDPK1LOXL2MAPTL3MBTL1CNR2
SCHEMBL20983568 0.87 LOXL2 (0.45) PDPK1LOXL2L3MBTL1DYRK1ALOXL3
SCHEMBL19274748 0.86 LOXL2 (0.37) PDPK1LOXL2DYRK1ALOXL3
SCHEMBL19274631 0.86 ESR1 (0.38) PDPK1MAPTKMT2AL3MBTL1ESR1
SCHEMBL19274495 0.86 PDPK1 (0.38) PDPK1MAPTKMT2AL3MBTL1ESR1
SCHEMBL29971303 0.80 LOXL2 (0.45) PDPK1LOXL2LOXL3
SCHEMBL19259891 0.77 LOXL2 (0.46) PDPK1LOXL2DYRK1ALOXL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 WO disclosed